ARDELYX, INC. (ARDX) Form 10-Q — Nov 3, 2026
Ardelyx reported Q3 2026 total revenue of $127.7 million, up 16% year over year, with net product sales of $125.5 million (+19%), driven by IBSRELA at $96.3 million and XPHOZAH at $29.2 million. The company posted a quarterly net loss of just $0.7 million and positive income from operations of $4.0 million, with nine-month operating cash burn improving 43% to $36.5 million.
Key figures
- Eps
- -$0.22 (nine months 2026)
- Revenue
- 127655000
- Total Debt
- 252360000
- Revenue Yoy
- 16% Q3 total revenue growth; 22% nine-month growth ($343.0M vs $282.1M)
- Total Assets
- 587525000
- Cash Position
- 285338000
- Shares Outstanding
- 251372553
- Atm program
- $100.0M (no sales to date)
- Ibsrela q3 sales
- $96.3M vs $78.2M prior year
- Xphozah q3 sales
- $29.2M (+7% YoY)
- Accumulated deficit
- $1.0 billion
- Q3 product sales net
- $125.5M (+19% YoY)
- Term g loan available
- $50.0M (drawable through December 20, 2026)
- Q3 income from operations
- $4.0M (first positive quarter shown)
- Term loan principal outstanding
- $250.0M
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.